(Q38149327)

29 August 2017

title

Emerging tyrosine kinase inhibitors for head and neck cancer (English)

1 reference

29 August 2017

Laura Locati

2

0 references

Paolo Bossi

object named as

Paolo Bossi

series ordinal

1

0 references

Lisa Licitra

object named as

Lisa Licitra

series ordinal

3

0 references

language of work or name

English

0 references

publication date

5 October 2013

1 reference

Expert Opinion on Emerging Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

18

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

445-459

1 reference

29 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Human papillomavirus (HPV) in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Quality of life research in head and neck cancer: a review of the current state of the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

The role of the head and neck surgeon in contemporary multidisciplinary treatment programs for advanced head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Evidence-based organ-sparing radiotherapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

The expanding role of systemic therapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Should cetuximab replace cisplatin in head and neck cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.842976

10.1517/14728214.2013.842976

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference